The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The session will start with how low titer group O whole blood (LTOWB) has become part of the 21st-century massive transfusion protocol (MTP) of both adult and pediatric trauma and non-trauma settings with a focus on North America. The session will demonstrate how to design and implement an LTOWB program in both the blood center and transfusion service. There will be a discussion on matters important to blood centers, including the use of platelet-sparing leukoreduction filters, what is considered “low titer,” the possibility of manufacturing unused units into components, and recruitment concerns of a dedicated program. Transfusion service logistics will be covered, including availability and wastage. Rh (D) considerations, particularly in women of childbearing age and pediatric patients, will be an area of focus. The use of LTOWB prehospital and in-hospital and effects on patient outcomes will be addressed. The session will conclude with the future directions of LTOWB.
Learning Objectives:
Discuss the evolution of low-titer group O whole blood in the 21st century as part of the massive transfusion protocol in both adult and pediatric trauma and nontrauma patient with a focus on North America
Demonstrate how to design and implement a LTOWB program in both the blood center and transfusion service
Describe blood center logistics including recruiting the right donors
Evaluate transfusion service logistics including Rh considerations of women in childbearing years and pediatric patients.
Assess prehospital vs. in hospital transfusions and effects on outcomes
Nour
AlMozain,
MD,
Associate Consultant,
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Center
Amit
Tayal,
MD,
Director, Blood Bank and Stem Cell Laboratory, Assistant Professor,
West Virginia University School of Medicine and Robert C. Byrd Health Sciences Center
Disclosures
Nour AlMozain, MD:
Octapharma: Honoraria (Terminated, February 1, 2023); Terumo BCT: Honoraria (Terminated, March 31, 2023)